Menu Back toBrave New World: Early Clinical Trials in a Pandemic

DIA 2021 Global Annual Meeting


Brave New World: Early Clinical Trials in a Pandemic

Session Chair(s)

Anita  Nelsen

Anita Nelsen

  • Executive Vice President, Translational Medicine
  • Parexel, United States
This session will discuss the impact on early clinical research and development under COVID-19 and measures that were put in place to protect healthy volunteers and staff.
Learning Objective : To understand the impact on early clinical research and early drug development under COVID-19 pandemic conditions. To identify & refine safety measures and operational setup for volunteers/staff under COVID-19 pandemic conditions. To analyze the impact on the COVID-19 pandemic on early clinical research in general and in particular in Germany.

Speaker(s)

Sandra  Stark, PhD, MSc

SARS-CoV-2 Testing, Operational Challenges, and Subject Safety Considerations Under COVID-19 Pandemic Conditions: A New Era

Sandra Stark, PhD, MSc

  • Head Early Phase Clinical Unit Berlin
  • Parexel International, Germany
Jessie  Gu, PhD

Early Clinical Trials in a Pandemic: A Big Pharma Story

Jessie Gu, PhD

  • Executive Director, Global Head, Ph1 Clinical Pharmacology
  • Novartis Institutes for BioMedical Research (NIBR), United States